585 related articles for article (PubMed ID: 18329078)
21. Local control of prostate cancer by transrectal high intensity focused ultrasound therapy: preliminary results.
Gelet A; Chapelon JY; Bouvier R; Pangaud C; Lasne Y
J Urol; 1999 Jan; 161(1):156-62. PubMed ID: 10037389
[TBL] [Abstract][Full Text] [Related]
22. Value of prostate-specific antigen and prostate-specific antigen density in detection of prostate cancer in an Iranian population of men.
Ghafoori M; Varedi P; Hosseini SJ; Asgari M; Shakiba M
Urol J; 2009; 6(3):182-8. PubMed ID: 19711272
[TBL] [Abstract][Full Text] [Related]
23. Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable.
Hugosson J; Aus G; Lilja H; Lodding P; Pihl CG; Pileblad E
J Urol; 2003 May; 169(5):1720-3. PubMed ID: 12686817
[TBL] [Abstract][Full Text] [Related]
24. [Diagnosis of cancer of the prostate by determining the blood levels of specific prostatic antigen, rectal examination, and transrectal echography].
Isa Kroon WA; Robles JE; de Castro F; Rosell D; Abad JI; Zudaire JJ; Berián JM
Actas Urol Esp; 1993 Jun; 17(6):341-5; discussion 345-6. PubMed ID: 7690176
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of percent free prostate specific antigen as a predictor of prostate cancer detection on repeat biopsy.
Uemura H; Nakamura M; Hasumi H; Sugiura S; Fujinami K; Miyoshi Y; Yao M; Kubota Y
Int J Urol; 2004 Jul; 11(7):494-500. PubMed ID: 15242358
[TBL] [Abstract][Full Text] [Related]
26. Comparison of 6- and 12-core prostate biopsy in Taiwanese men: impact of total prostate-specific antigen, prostate-specific antigen density and prostate volume on prostate cancer detection.
Chiang IN; Chang SJ; Pu YS; Huang KH; Yu HJ; Huang CY
Urol Int; 2009; 82(3):270-5. PubMed ID: 19440012
[TBL] [Abstract][Full Text] [Related]
27. Predictive criteria for prostate cancer detection in men with serum PSA concentration of 2.0 to 4.0 ng/mL.
Kravchick S; Peled R; Dorfman D; Agulansky L; Ben-Dor D; Cytron S
Urology; 2005 Sep; 66(3):542-6. PubMed ID: 16140074
[TBL] [Abstract][Full Text] [Related]
28. Prospective identification of National Institutes of Health category IV prostatitis in men with elevated prostate specific antigen.
Potts JM
J Urol; 2000 Nov; 164(5):1550-3. PubMed ID: 11025702
[TBL] [Abstract][Full Text] [Related]
29. The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam.
Gosselaar C; Roobol MJ; Roemeling S; Schröder FH
Eur Urol; 2008 Sep; 54(3):581-8. PubMed ID: 18423977
[TBL] [Abstract][Full Text] [Related]
30. Influence of anthropometric measurements, age, and prostate volume on prostate-specific antigen levels in men with a low risk of prostate cancer.
Ochiai A; Fritsche HA; Babaian RJ
Urology; 2005 Oct; 66(4):819-23. PubMed ID: 16230145
[TBL] [Abstract][Full Text] [Related]
31. Prostatic transition zone biopsies in men with previous negative biopsies and persistently elevated serum prostate specific antigen values.
Keetch DW; Catalona WJ
J Urol; 1995 Nov; 154(5):1795-7. PubMed ID: 7563349
[TBL] [Abstract][Full Text] [Related]
32. The potential role of prebiopsy magnetic resonance imaging combined with prostate-specific antigen density in the detection of prostate cancer.
Kubota Y; Kamei S; Nakano M; Ehara H; Deguchi T; Tanaka O
Int J Urol; 2008 Apr; 15(4):322-6; discussion 327. PubMed ID: 18380820
[TBL] [Abstract][Full Text] [Related]
33. Prostate specific antigen adjusted for transition zone epithelial volume: the powerful predictor for the detection of prostate cancer on repeat biopsy.
Ohigashi T; Kanao K; Kikuchi E; Nakagawa K; Nakashima J; Marumo K; Murai M
J Urol; 2005 May; 173(5):1541-5. PubMed ID: 15821482
[TBL] [Abstract][Full Text] [Related]
34. Diagnosis of prostate cancer in patients with an elevated prostate-specific antigen level: role of endorectal MRI and MR spectroscopic imaging.
Costouros NG; Coakley FV; Westphalen AC; Qayyum A; Yeh BM; Joe BN; Kurhanewicz J
AJR Am J Roentgenol; 2007 Mar; 188(3):812-6. PubMed ID: 17312072
[TBL] [Abstract][Full Text] [Related]
35. Prebiopsy PSA velocity not reliable predictor of prostate cancer diagnosis, Gleason score, tumor location, or cancer volume after TTMB.
Bittner N; Merrick GS; Andreini H; Taubenslag W; Allen ZA; Butler WM; Anderson RL; Adamovich E; Wallner KE
Urology; 2009 Jul; 74(1):171-6. PubMed ID: 19232691
[TBL] [Abstract][Full Text] [Related]
36. Prostate cancer screening with prostate-specific antigen in hemodialysis patients.
Horinaga M; Kitamura K; Saito S; Ukimura O; Nakanoma T; Okihara K; Kitagawa M; Nakanishi H; Miki T
Urol Int; 2007; 78(4):334-7. PubMed ID: 17495492
[TBL] [Abstract][Full Text] [Related]
37. Urinary/serum prostate-specific antigen ratio: comparison with free/total serum prostate-specific antigen ratio in improving prostate cancer detection.
Irani J; Salomon L; Soulié M; Zlotta A; de la Taille A; Doré B; Millet C
Urology; 2005 Mar; 65(3):533-7. PubMed ID: 15780371
[TBL] [Abstract][Full Text] [Related]
38. Treatment of chronic prostatitis lowers serum prostate specific antigen.
Bozeman CB; Carver BS; Eastham JA; Venable DD
J Urol; 2002 Apr; 167(4):1723-6. PubMed ID: 11912396
[TBL] [Abstract][Full Text] [Related]
39. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
Schröder FH; Bangma CH; Roobol MJ
Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712
[TBL] [Abstract][Full Text] [Related]
40. Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer.
Berger AP; Deibl M; Strasak A; Bektic J; Pelzer AE; Klocker H; Steiner H; Fritsche G; Bartsch G; Horninger W
Urology; 2007 Jan; 69(1):134-8. PubMed ID: 17270635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
